Market Data
Market Cap₹3,550.64 Cr.
52W High₹419.45
Current Price₹408.3
52W Low₹87
Down from 52W High2.7 %
Face Value₹10
Performance
ROCE5.15 %
ROE4.14 %
EPS (TTM)₹2.84
EPS Prev Qtr₹1.81
EPS Last Year₹1
EBITDA Qtr₹25.85 Cr.
Book Value₹159
Financial Health
Debt/Equity0.01
Debt/Profit0.31
Total Assets₹1,673.35 Cr.
Promoter Holding42.93 %
Earning Power1.68 %
Valuation
Stock P/E59.87
Industry P/E33.81
Price to Book2.57
Price to Sales5.34
Graham Number₹156.14
Key Metrics
Face Value
₹10
About Ind-Swift Laboratories Ltd
Healthcare · Pharmaceuticals
Ind-Swift Laboratories Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹10. Market cap ₹3,550.64 Cr.
Price Chart
Strengths & Weaknesses
Strengths
- The company has a manageable debt-to-equity ratio of 0.04, indicating low financial leverage.
- The promoter holding stands at 42.93%, suggesting strong control and alignment of interests.
Weaknesses
- The P/E ratio of 56.92 is relatively high, indicating that the stock may be overvalued compared to peers.
- The P/B ratio of 3.07 suggests that the market values the company at a premium over its book value.
- The ROCE of 6.34% and ROE of 5.21% are relatively low, indicating inefficient use of capital and potential challenges in generating higher returns.
- The dividend yield is N/A, indicating that the company does not currently pay dividends, which may be a concern for income-focused investors.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.51 | ₹4,41,477.63 Cr | 0.87% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 86.48 | ₹2,53,031.38 Cr | 0.31% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 77.67 | ₹1,85,216.32 Cr | 0.78% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 27.01 | ₹1,20,897.46 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.28 | ₹1,12,201.64 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 99.31 | ₹1,08,698.22 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Dr Reddys Laboratories Ltd | - | 31.6 | ₹1,02,039.12 Cr | 0.65% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Mankind Pharma Ltd | - | 49.29 | ₹1,00,752.43 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Aurobindo Pharma Ltd | - | 26.56 | ₹97,814.24 Cr | 0.24% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.64 | ₹94,274.49 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 36.67 | ₹65,922.11 Cr | 0.11% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 28.65 | ₹61,804.34 Cr | 1.03% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 110.29 | ₹61,113.53 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.22 | ₹56,860.69 Cr | 1.78% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 46.73 | ₹49,091.33 Cr | 1.97% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ipca Laboratories Ltd | - | 36.13 | ₹48,712.48 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 83.03 | ₹47,949.68 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Gland Pharma Ltd | - | 42.26 | ₹47,764.08 Cr | 0.69% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ajanta Pharma Ltd | - | 38.87 | ₹44,109.77 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Sales | 152.64 | 150.85 | 169.79 | 191.45 |
| ↳ QoQ Growth | - | -1.2% | +12.6% | +12.8% |
| Expenses | 158.15 | 155.51 | 157.33 | 165.6 |
| Operating Profit | -5.5 | -4.66 | 12.45 | 25.85 |
| OPM % | -3.6% | -3.09% | 7.33% | 13.5% |
| Other Income | 17.86 | 27.58 | 2.22 | 7.65 |
| Interest | 2.01 | 0.67 | -2.43 | 0.71 |
| Depreciation | 6.98 | 8.84 | 8.12 | 7.58 |
| EBITDA | 1.48 | 4.18 | 20.57 | 33.43 |
| EBITDA Margin % | 0.97% | 2.77% | 12.11% | 17.46% |
| Profit Before Tax | 10.34 | 16.39 | 11.96 | 32.56 |
| Tax % | 22.24% | 41.92% | -26.34% | 24.54% |
| Net Profit | 8.04 | 9.52 | 15.11 | 24.57 |
| ↳ QoQ Growth | - | +18.4% | +58.7% | +62.6% |
| EPS | 1 | 1.17 | 1.81 | 2.84 |
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 68.74 | 86.8366 |
| Reserves | 1104.26 | 1297.1869 |
| Borrowings | 40.85 | 17.7 |
| Other Liabilities | 224.49 | 271.63 |
| Total Liabilities | 1438.34 | 1673.3499 |
| Fixed Assets | 262.33 | 303.7758 |
| CWIP | 0 | 10.2022 |
| Investments | 213.46 | 249.73 |
| Other Assets | 962.55 | 1109.64 |
| Total Assets | 1438.34 | 1673.3499 |
Cash Flows
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Cash from Operating Activity | -25.4735 | -68.1685 |
| Cash from Investing Activity | -109.6222 | -72.6832 |
| Cash from Financing Activity | 69.2046 | 141.8086 |
| Net Cash Flow | -65.8911 | 0.9569 |
Shareholding Pattern
| Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|
| Promoters % | 39.5% | 42.99% | 42.93% |
| FIIs % | 14.33% | 13.88% | 10.7% |
| DIIs % | 0.68% | 0% | 0.17% |
| Public % | 35.06% | 32.9% | 34.45% |
| No. of Shareholders | 42,121 | 39,222 | 40,881 |
Major Shareholders (>1%)
- Essix Biosciences LimitedPromoter and Promoter Group37.81%
- Zeal Global Opportunities FundPublic Shareholding4.62%
- Nova Global Opportunities Fund Pcc - TouchstonePublic Shareholding2.96%
- Panchkula Finvest Private LimitedPublic Shareholding2.41%
As of 2026-06-30View all shareholders →